On June 25, 2009, Chen, Li; Dillon, Michael Patrick; Feng, Lichun; Hawley, Ronald Charles; Yang, Minmin published a patent.Application of 1162054-86-5 The title of the patent was Preparation of imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists for disease treatment. And the patent contained the following:
Compounds of the formula I (wherein R1 is (un)substituted imidazolyl; R2 is Ph, pyridinyl, pyrimidinyl, etc., all optionally substituted; R3 is H, C1-6-alkyl, hetero-C1-6-alkyl, or CN; R4 is H, C1-6-alkyl, or hetero-C1-6-alkyl; or R3 and R4 together form part of a ring; R5 is C1-6alkyl, hetero-C1-6alkyl; halo-C1-6alkyl, etc.; or R3, R4, and R5 together form part of a ring; and R6, R7 and R8 are independently H, C1-6-alkyl, C1-6-alkyloxy, halo, C1-6-haloalkyl, or CN) are provided herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds More particularly I are usable for treatment of genitourinary, pain, inflammatory, gastrointestinal and respiratory diseases, conditions and disorders. Example compound II was prepared by reacting imidazole with the appropriate 5-iodobiphenylcarboxamide intermediate. In a P2X3 FLIPR (fluorometric imaging plate reader) assay, example compound III had a pIC50 of approx. 8.55 for the P2X3 receptor. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Application of 1162054-86-5
The Article related to imidazole arylamide preparation p2x3 p2x2 receptor antagonist disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application of 1162054-86-5
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem